TempTraq Patient vs CARTOX

***** FOR CLINICAL USE ONLY ***** TempTraq® is a Bluetooth® continuous temperature monitor in the form of a one-time use, disposable patch. The patch senses, records and transmits body temperature via Bluetooth® Version 4.0. Temperature information from the patch is monitored using an iOS device (with Bluetooth® Version 4.0 capability running the TempTraq Patient app). TempTraq measures under-the-arm axillary temperature and this is converted to an oral temperature which is displayed in the TempTraq Patient app and transmitted to the TempTraq Connect cloud service for viewing by clinicians. The TempTraq Connect clinical system enables remote continuous monitoring of patient temperature by clinicians. The system consists of the TempTraq patch worn by the patient, a patient smart device running the TempTraq Patient app which collects and sends temperature data to the TempTraq Connect cloud service, and the TempTraq Clinician Web Application. The TempTraq Patient application provides the patient monitoring functionality, receiving temperature data broadcast from the TempTraq patch and transmitting the data to the TempTraq Connect cloud service enabling the data to be monitored by clinicians. Important: The information in this app is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. You are encouraged to confirm any information obtained from or through this app regarding any medical condition or treatment with your physician. NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY SEEKING MEDICAL TREATMENT BECAUSE OF SOMETHING YOU HAVE READ ON OR ACCESSED THROUGH THIS APP.

Cellular therapies can be associated with unique, acute toxicities which can be severe or even fatal if not identified early and treated appropriately. Cytokine Release Syndrome (CRS), the most commonly observed toxicity can range in severity from low-grade constitutional symptoms to high-grade syndrome associated with life-threatening multi-organ disfunction. Neurotoxicity, originally termed CRES (CAR-Related Encephalopathy Syndrome) and now updated to ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) is the second most-common adverse even and can occur concurrently with CRS. A multi-disciplinary working group was formed to address safety issues for patients receiving cellular therapy which led to the development of new grading methods and treatment algorithms that have been incorporated into the CARTOX mobile app. The CARTOX mobile app assists with grading toxicities, managing toxicities and assists with recommendations regarding appropriate antimicrobial prophylaxis for patients who have received immune effector cell therapy. Users are more easily able to determine if the patient is having cytokine release syndrome or neurotoxicity and to grade those toxicities. Intended audience: Clinicians (physicians, nurse practitioners, physician assistants, pharmacists, nurses) who treat/care for patients receiving immune effector cells.